As the pharmaceutical industry grapples with escalating R&D costs to take new drugs to the market amid shrinking healthcare budgets, medical teams at drug firms are increasingly engaging not just with physicians but also emerging key stakeholders such as the formulary pharmacists and payors.
Natasha Monin, UCB's regional medical director (neurology) for the Asia Pacific region, said that the "evolution of expectations" around the role of MSLs has been driven by multiple factors including changes in the ecosystem and regulators
